Evidence map›Paper›PMID 30177746›Full record

ArticleScientific reports2018

Y1 receptor deficiency in β-cells leads to increased adiposity and impaired glucose metabolism.

Kim Loh, Yan-Chuan Shi, Mohammed Bensellam, Kailun Lee, D Ross Laybutt, Herbert Herzog

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. PYY, a Therapeutic Option for Type 2 Diabetes?Clinical medicine insights. Endocrinology and diabetes · 2020
    Review
  6. Nonclassical Islet Peptides: Pancreatic and Extrapancreatic Actions.Clinical medicine insights. Endocrinology and diabetes · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kim LohNeuroscience Division, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, 2010, Australia. kloh@svi.edu.au.
Yan-Chuan ShiNeuroscience Division, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, 2010, Australia.ORCID 0000-0002-8368-6735
Mohammed BensellamDiabetes and Metabolism Division, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, 2010, Australia.
Kailun LeeNeuroscience Division, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, 2010, Australia.
D Ross LaybuttDiabetes and Metabolism Division, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, 2010, Australia.
Herbert HerzogNeuroscience Division, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, 2010, Australia. h.herzog@garvan.org.au.
Garvan Institute of Medical Research · AU

Funding

Australian Diabetes Society (ADS) FellowshipsDepartment of Health | National Health and Medical Research Council (NHMRC) APP101973Department of Health | National Health and Medical Research Council (NHMRC) APP1028882Department of Health | National Health and Medical Research Council (NHMRC) APP1080473Diabetes Australia Research Trust (DART) Y13G-LOHK
6 · The paper itself

Abstract

Insulin secretion from pancreatic β-cells is critical for maintaining glucose homeostasis and deregulation of circulating insulin levels is associated with the development of metabolic diseases. While many factors have been implicated in the stimulation of insulin secretion, the mechanisms that subsequently reduce insulin secretion remain largely unexplored. Here we demonstrate that mice with β-cell specific ablation of the Y1 receptor exhibit significantly upregulated serum insulin levels associated with increased body weight and adiposity. Interestingly, when challenged with a high fat diet these β-cell specific Y1-deficient mice also develop hyperglycaemia and impaired glucose tolerance. This is most likely due to enhanced hepatic lipid synthesis, resulting in an increase of lipid accumulation in the liver. Together, our study demonstrates that Y1 receptor signaling negatively regulates insulin release, and pharmacological inhibition of Y1 receptor signalling for the treatment of non-insulin dependent diabetes should be taken into careful consideration.

Indexed as

AdiposityAnimalsDiabetes Mellitus, Type 2Diet, High-FatDisease Models, AnimalGlucoseHomeostasisHumansInsulinInsulin-Secreting CellsLipid MetabolismLiverMiceMice, Inbred C57BLMice, KnockoutReceptors, Neuropeptide YGlucoseInsulinneuropeptide Y-Y1 receptorReceptors, Neuropeptide Y

Identifiers

PMID30177746
PMCPMC6120893
OpenAlexW2887550150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.